Ian Hagemann, Md, PhD

Medical School Department Pathology and Immunology
Research Program Solid Tumor Therapeutics
Ian Hagemann

Researcher Background

Primary Academic Title

Professor, Department of Pathology and Immunology, WashU Medicine

Training

  • 2008 - 2011: Resident in Anatomic Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA
  • 2010 - 2011: Chief Resident, Anatomic Pathology , Hospital of the University of Pennsylvania, Philadelphia, PA
  • 2011 - 2012: Fellow in Selective (Surgical) Pathology, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO
  • 2012 - 2013: Fellow in Molecular Genetic Pathology, Washington University, St. Louis, MO

Education

  • 2008: MD, Washington University School of Medicine, St. Louis, MO
  • 2008: PhD, Washington University School of Medicine, St. Louis, MO

Research & Selected Publications

Research Interest

Clinical and translational research on the gentic and epigenetic basis of gynecologic cancers

Research publications

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
Authors:

Kong T, Mabry A, Highkin M, one or more additional authors omitted Hagemann IS, one or more additional authors omitted Ma CX

Journal & Year:

Nat Commun • 2026

Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity.
Authors:

Davis AA, Jaeger E, Hagemann IS, one or more additional authors omitted Cristofanilli M

Journal & Year:

Clin Cancer Res • 2025

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.
Authors:

Schab A, Compadre A, Drexler R, one or more additional authors omitted Hagemann IS, one or more additional authors omitted Mullen MM

Journal & Year:

J Clin Invest • 2025

Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.
Authors:

Zhang X, Goedegebuure SP, Chen MY, one or more additional authors omitted Hagemann IS, one or more additional authors omitted Gillanders WE

Journal & Year:

Genome Med • 2024

Tumour evolution and microenvironment interactions in 2D and 3D space.
Authors:

Mo CK, Liu J, Chen S, one or more additional authors omitted Hagemann IS, one or more additional authors omitted Ding L

Journal & Year:

Nature • 2024

Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Gro…
Authors:

Hagemann IS, Deng W, Zaino RJ, one or more additional authors omitted Mutch DG

Journal & Year:

Gynecol Oncol • 2023

Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma.
Authors:

Hagemann IS, Bridge JA, Tafe LJ, one or more additional authors omitted Yemelyanova A

Journal & Year:

Arch Pathol Lab Med • 2023

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.
Authors:

Cheng X, Sun Y, Highkin M, one or more additional authors omitted Hagemann IS, one or more additional authors omitted Bose R

Journal & Year:

Cancer Res • 2023